Selling Your Veterinary Practice to VCA: A Vet’s 2026 Guide

Key takeaways

• VCA Animal Hospitals operates approximately 1,000 general practice and specialty hospitals across the United States, the largest US footprint of any single veterinary practice brand per VCA company materials.
• VCA has been owned by Mars, Incorporated since 2017, when Mars acquired the then-publicly-traded VCA Inc. for approximately $9.1 billion per the SEC filings at the time.
• VCA is part of Mars Veterinary Health, the division of Mars that also includes Banfield Pet Hospital, BluePearl Specialty and Emergency Pet Hospital, and Antech Diagnostics in the United States.
• Brand handling is the most important VCA-specific negotiation point. Per VCA company materials and the historical pattern, VCA’s integration has emphasized brand consolidation over time. Sellers whose practice has decades of local goodwill should confirm specific brand handling in writing as part of the definitive purchase agreement.
• The most reliable way to know what VCA — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. VCA is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

Most VCA conversations I walk into with a practice owner start the same way. The owner is on the receiving end of a careful, well-paced sequence of outreach from a major buyer’s acquisition team.

The most recent message has named a specific number — not a range, a number — and asked for a structured call to walk through what acquisition would mean for the practice and the staff. The pitch is some combination of the operational platform, the continuing-education depth, the integrated diagnostics, and the long-horizon ownership structure.

The owner I’m sitting across from is usually less interested in the multiple than in what survives the transaction. The practice name.

The local identity. The family signage that’s been above the door for decades.

The team that’s been together for a generation. Almost every VCA conversation eventually circles back to a version of the same question: will it still be the practice I built in year five, or will the brand and identity be something different?

That brand-handling question is the through-line for the VCA conversation more than for almost any other major US veterinary buyer. Other major buyers earn their differentiation on dimensions that matter — fund cycle, deal structure, integration philosophy — but the dimension that most affects post-sale outcomes for the typical seller evaluating VCA is how the brand and the practice identity move over a defined integration timeline.

What follows is the same picture I’d lay out over dinner if a vet handed me a VCA offer and asked what to do with it. Who VCA is, how they value practices, how the integration unfolds, where the negotiation leverage actually sits, and how to think about VCA against the other buyers who’d compete for the same practice in a properly run process.

Quick facts on VCA Animal Hospitals

VCA Animal Hospitals is the largest veterinary practice brand in the United States by hospital count. VCA operates approximately 1,000 hospitals nationwide per VCA company materials, with a mix of general practice and specialty hospitals across most major metropolitan areas.

VCA was founded in 1986 and went public in the 1990s, growing through acquisitions over the next three decades to become the dominant US veterinary brand by footprint. In 2017, Mars, Incorporated acquired VCA in a transaction valued at approximately $9.1 billion per the SEC filings at the time.

The acquisition consolidated VCA with Mars’s existing pet health platforms (Banfield, BluePearl) under the newly-formed Mars Veterinary Health umbrella.

VCA’s headquarters are in Los Angeles, California. The company’s core operations include the general practice and specialty hospital network, the integrated Antech Diagnostics reference laboratory platform, and a continuing education programming arm that serves doctors across the network.

Antech was part of the original VCA acquisition and continues to operate as the Mars-owned reference lab platform across VCA, BluePearl, and many independent practices.

The most important fact for a US seller to internalize. VCA is owned by Mars, Incorporated, a family-owned strategic. Mars is one of the largest privately-held companies in the world and has no defined exit cycle on any of its acquisitions. That ownership structure is fundamentally different from the private equity-backed consolidators that make up the rest of the buyer pool.

For a deeper analysis of the Mars umbrella and its strategic posture, see our Mars Veterinary Health buyer profile.

What VCA actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice receives a direct offer from any major buyer’s acquisition team — VCA included — the offer reflects the leverage the buyer perceives in the conversation. A single bidder with no visible competition has no structural reason to put forward their strongest cash percentage, their tightest earnout protections, their most explicit brand-preservation language, or their most flexible non-compete terms in that first conversation.

Inside a properly structured competitive process, where the buyer knows other qualified bidders are underwriting the same practice in parallel, every one of those dimensions tends to move — sometimes meaningfully. The pattern is not unique to VCA.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room, and it is why a practice owner is consistently better served by seeing the full field before committing to any one buyer’s structure.

VCA does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

The actual number for any specific practice depends heavily on whether other buyers are at the table and the specific profile of the practice. VCA participates in this competitive band when they bid on qualifying practices, with the specific offer on any specific deal negotiated case by case under confidentiality.

For specialty hospitals, the broader market generally values these higher than comparable GP practices per industry research. VCA operates a substantial specialty hospital footprint within its broader US network, and VCA participates as a bidder for qualifying specialty platforms when they fit the criteria.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range typically extends higher than for single-location GP practices, with deal sizes scaling into the eight-figure-plus range. VCA’s acquisition capacity and the strategic backing of Mars mean VCA is an active bidder for larger platforms when the practice profile matches strategic fit.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward regional PE-backed groups, smaller consolidators, and individual buyers. Specific VCA acquisition criteria are not publicly published and may vary by region and strategic priority.

The cash-at-close reality

The headline number on a VCA offer letter is the figure most owners fixate on. The figure that actually determines what arrives in your account at closing is the structured cash-at-close — the wire that hits the bank on the day the documents sign.

The figure that determines what arrives across the following several years is the structure of the earnout, the retained equity (if any), and the seller note (if any). For VCA-affiliated offers specifically, the typical structure follows the broader major-buyer pattern documented in 2025-2026 healthcare M&A commentary from Dechert LLP, Holland & Knight, and Capstone Partners: most of the total deal value lands as cash on the closing date, and the remainder is split across the contingent components.

The Mars-affiliated structure has one practical wrinkle that PE-backed offers usually don’t have. A retained-equity stake in a PE-backed buyer eventually liquidates at the platform’s exit event — the next sponsor sale, the recapitalization, the IPO.

The Mars-affiliated equivalent has no analogous exit cycle, because Mars’s family ownership has no defined sale horizon. That changes the rollover math substantially.

Where VCA includes retained equity in the deal, the negotiation should center on contractually defined liquidity windows, put/call mechanics tied to specific calendar milestones, and an explicit formula price — because relying on a platform exit event to monetize the retained equity is structurally different at a family-held strategic than at a PE-backed platform.

A note on deal structure types in the current market

The shape of US veterinary M&A deals has shifted measurably over the past 18 months. MB Law Firm’s 2025 healthcare M&A commentary documents a sustained move toward partnership and joint-venture structures across the PE-backed buyer pool — co-ownership models in which the buyer acquires a majority stake (commonly 60 to 80 percent), the seller retains a meaningful minority position (commonly 20 to 40 percent) as direct equity in the practice entity itself, and a contractual put/call mechanism governs the eventual buyout.

Rarebreed Veterinary Partners has made partnership the centerpiece of its company-materials messaging. The legacy SVP playbook (now part of Mission Pet Health) leans heavily on co-ownership.

IVC Evidensia and Encore Vet Group both publicly market partnership variants.

The question worth asking of any VCA offer is whether a partnership-structure alternative is on the table alongside the standard 100 percent acquisition. VCA’s deal structures are negotiated under confidentiality and the standard posture is not publicly enumerated, so the answer comes from the conversation, not from VCA’s published materials.

The structural reality is that a Mars-affiliated partnership would operate on different timing mechanics than a PE-backed partnership — the family-ownership horizon means the put/call window cannot be anchored to a fund’s exit cycle the way a PE-backed partnership’s typically is. Our PE pricing guide walks through the structure-by-structure comparison.

How VCA’s acquisition team operates

VCA runs one of the longest-tenured corporate-development teams in US veterinary M&A. Per VCA company materials, the team’s sourcing emphasis falls heavily on practices situated in markets where VCA already operates regional density — geographic clustering matters to VCA because the back-office, referral, and operational synergies that justify the multiple are easier to deliver when the acquired practice sits inside an existing VCA market footprint.

The team works three primary channels: direct outreach to practice owners they’ve identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners who reach out independently.

A practical implication for sellers: if your practice is in a market where VCA already has multiple hospitals, you are likely to receive direct outreach at some point. If your practice is in a market where VCA has little or no existing presence, the team is less likely to initiate outreach but will still bid when invited into a competitive process where the practice profile is strong.

Either way, VCA’s bidding behavior is meaningfully sharper inside a structured competitive process than in a direct one-on-one conversation — that pattern is consistent across the major buyer pool.

How VCA integrates the practices it acquires

VCA’s integration approach is more identity-shifting than most of the other major US veterinary buyers, which is the most important practical fact for any seller evaluating a VCA offer.

Brand consolidation over time. Per VCA company materials and the historical pattern, VCA’s integration approach has emphasized brand transition under the VCA name on a timeline determined under the definitive purchase agreement. The specific timing and approach for any acquired practice are negotiated case by case.

For sellers whose practice has decades of local goodwill, this is the dimension that most affects post-sale staff and client retention, and it deserves the most explicit attention in the deal terms.

Shared back office. Per VCA company materials, the VCA platform provides centralized HR, accounting, payroll, vendor management, supply purchasing, and IT support. The integration timing and approach are determined case by case under the VCA regional operating structure.

Antech Diagnostics integration. VCA practices use Antech Diagnostics as the reference laboratory platform per VCA company materials. For sellers whose practice already uses Antech, the integration is invisible; for sellers whose practice uses Idexx or another competing lab, the integration involves a lab transition.

Centralized marketing. Local marketing initiatives often consolidate into VCA’s regional or national marketing programs over the integration period. The practice’s website typically migrates to VCA’s content management platform, often on a timeline aligned with the broader brand transition.

Continuing education and clinical programs. VCA invests meaningfully in continuing education and clinical programming for the doctors in its network per VCA company materials. This is one of the genuine value-adds VCA offers practitioners who join the platform.

Doctor relationships. Per industry M&A commentary on major veterinary acquirers, selling owners commonly stay on as medical directors for 3 to 5 years post-close, providing continuity to staff and clients during the integration period. VCA follows this general pattern, with the specific terms negotiated case by case under the definitive purchase agreement.

VCA’s recent activity in 2025-2026

VCA enters 2026 with one of the most consistent multi-year acquisition cadences in the US veterinary buyer pool. Capstone Partners‘ April 2026 Pet Sector M&A Update reports that total US veterinary deal volume accelerated meaningfully in the first quarter of 2026 against the comparable window of 2025, with both PE-backed roll-ups and strategic acquirers — Mars-affiliated entities included — running active pipelines.

The trade press coverage of VCA-attributed transactions in 2025 and the early-2026 windows is consistent with VCA’s historical pace, though specific acquisition counts are not publicly itemized by VCA in real time.

The practical read for an owner receiving 2026 VCA outreach: this is not a buyer that’s pulling back from the market, and the offer in your hand is not the bottom of their range. The way to discover where the top of their range actually is, on your specific practice, is to put them in a properly structured competitive process where they know other qualified bidders are working the same numbers on the same timeline.

Have an offer from VCA? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How VCA compares to the other major buyers

If you’re considering VCA, you’re probably comparing them implicitly to the other major buyers who’d compete for your practice. Here’s how VCA stacks up across the dimensions that matter.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, the Luxembourg-based privately-held investment vehicle of the Reimann family. Both VCA and NVA are owned by privately-held strategic / long-hold investment groups, distinguishing them from the PE-backed fund-cycle buyers.

NVA’s general approach is to preserve local practice branding per NVA company materials, which is structurally different from VCA’s historical brand consolidation approach. Both VCA and NVA participate in competitive sale processes for qualifying practices, with the specific deal terms determined case by case.

Our NVA buyer profile covers the NVA-specific dimensions in depth.

Versus AmeriVet Veterinary Partners. AmeriVet is PE-backed (AEA Investors and Oaktree Capital per public ownership disclosures) and is among the active 2026 mid-market acquirers per AmeriVet company materials. AmeriVet’s brand approach has historically emphasized local practice identity preservation per AmeriVet company materials, which contrasts with VCA’s historical brand consolidation pattern.

Both VCA and AmeriVet may compete for qualifying practices in a structured sale process; the specific deal terms are determined case by case.

Versus VetCor (Harvest Partners). VetCor is PE-backed and one of the longer-established US veterinary consolidators per VetCor company materials. VetCor’s integration approach has historically emphasized local brand preservation per VetCor company materials.

For sellers prioritizing brand preservation, that distinction is one of the most important factors when comparing VCA to VetCor.

Versus Mission Pet Health. Mission Pet Health, the post-merger entity formed from SVP and MVP per the July 2025 Mission Pet Health press release, is an active 2026 acquirer with a meaningful Southeast and Sun Belt footprint. Both VCA and Mission Pet Health may compete for qualifying practices in a structured sale process; specific deal terms and cultural fit are best evaluated in context per practice.

Versus BluePearl (Mars sub-brand). BluePearl is the Mars-affiliated specialty and emergency hospital brand. For specialty hospital sellers, BluePearl is more often the relevant Mars-affiliated bidder than VCA, though VCA’s specialty footprint means VCA also bids on qualifying specialty platforms.

BluePearl operates acquired hospitals under the BluePearl brand per BluePearl company materials.

Versus the smaller PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Heartland, VPP, others). Each has its own integration philosophy and target profile. Smaller groups sometimes pay more aggressively for practices that fill specific geographic or specialty gaps in their portfolio.

The right way to evaluate which buyer pays most is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with VCA

Six priorities when negotiating with VCA’s acquisition team.

Brand handling and integration timeline. The most important VCA-specific negotiation term. The historical pattern across VCA acquisitions has been brand consolidation under the VCA name on a timeline determined under the definitive purchase agreement.

For sellers whose practice has decades of local goodwill, this term materially affects post-sale staff and client retention. Confirm specific brand handling in writing as part of the deal: name, signage, website, marketing materials, and the precise timing of any planned brand transition.

If local identity matters to your post-sale outcomes, negotiate explicit brand preservation language, an extended preservation period, or a co-branded transition that protects local recognition.

Cash at close percentage. Offers in this market generally lean toward the majority of total deal value as cash at close, but the specific percentage VCA initially proposes varies deal by deal. Push for higher cash percentages.

Every dollar shifted from contingent to cash is guaranteed money instead of conditional.

Earnout structure. Earnouts commonly run on multi-year EBITDA targets. Push for shorter duration.

Push for revenue-based metrics where possible (the seller has more control over revenue post-close than over EBITDA, which depends on cost decisions the buyer makes). Insist on protective provisions: no major operational changes without seller consent, working capital floor, prohibition on shifting expenses from other VCA practices to the seller’s practice.

Rollover equity terms. If VCA includes rollover in their offer structure, negotiate the liquidity provision carefully. The Mars family-ownership horizon is materially longer than a PE fund cycle, so the timing of any retained-equity buyout deserves explicit contractual mechanics — defined liquidity windows, milestone-tied put/call mechanics, or a formula-priced buyout at a specified date.

Get governance rights: minority protection clauses, information rights, anti-dilution provisions.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. That can effectively end your career if you might want to continue practicing somewhere later.

Negotiate: shorter duration (1 to 2 years), tighter radius (5 to 10 miles), or carve out specific specialty or modality if you might continue clinical work post-employment.

Post-sale role and clinical autonomy. Medical director arrangements are standard. The protective terms that matter: clinical autonomy (you make medicine decisions, not the regional team), staffing autonomy (you keep the team you’ve trained), and a clear definition of which business decisions stay with you versus migrating to the VCA regional operating structure.

The integration roadmap should be in writing.

The brand handling question, in depth

For most sellers evaluating a VCA offer, the practical question is whether the practice they built becomes “a VCA hospital” or stays “Dr. Last Name’s Animal Hospital, a VCA practice.” The answer matters because it directly affects:

Staff retention. Long-tenured staff members are typically attached to the practice identity, not the corporate parent. A sharp brand transition can trigger turnover that takes years to recover from.

A negotiated brand preservation period gives the integrating practice time to demonstrate that the post-sale culture is acceptable before the brand change tests staff loyalty.

Client retention. Established client relationships in veterinary medicine are often built around the practice name and the doctors as a unified identity. A brand change is a moment when some portion of the client base reconsiders their veterinary relationship.

Practices in markets with strong independent competition are most exposed to this dynamic; practices in markets without strong alternatives are more insulated.

Seller’s earnout outcome. If the seller’s earnout is tied to practice-level EBITDA performance, anything that affects revenue or margin in the earnout period — including staff turnover and client attrition driven by a brand transition — affects the earnout payout. The brand-handling clause and the earnout structure are mechanically linked: a more aggressive brand transition timeline raises the risk that the earnout underperforms.

The protective negotiation positions worth pushing for: an explicit brand preservation period (often 2 to 5 years), defined criteria that must be met before any brand transition, the right to maintain the practice name on signage and marketing materials throughout the period, and an earnout structure that accounts for the integration risk if brand consolidation does occur.

Should I take a VCA offer or run a competitive process?

For VCA more than for almost any other US veterinary buyer, the competitive process produces leverage on the dimension that most affects the typical seller’s post-sale life: brand handling. A direct, single-bidder conversation with VCA will surface VCA’s standard integration approach — typically a defined-timeline brand transition under the VCA name.

The competitive process changes that calculus because every bidder, VCA included, knows the seller has alternative offers on the table that may include explicit indefinite brand preservation. What VCA puts forward on THIS deal is not the same thing as what VCA would put forward in a direct conversation.

The mechanical reason is straightforward: without competition, no buyer has incentive to bid against the ceiling of their own valuation comfort zone. They can pace the timeline, structure terms to favor the buyer side of the table, and tighten exclusivity.

With competition, the dynamics invert. Every term becomes negotiable because every bidder knows the seller has alternatives.

Cash percentage, earnout structure, rollover mechanics, non-compete radius, post-sale clinical autonomy, integration roadmap, brand-handling clause — each of these moves when the bidding window is genuinely competitive.

VCA participates in well-run competitive processes when invited. The VCA-specific terms that matter most to most sellers — the brand-preservation language, the integration timeline, the rollover liquidity mechanics — get materially better attention from the VCA team when they know other qualified buyers are underwriting the same practice in parallel inside a defined bidding window.

What our Elite Selling System actually does

The Elite Selling System is organized around a single observation: in a private, time-boxed auction of curated qualified buyers, the highest-quality bidders compete hardest for the highest-quality practices, and every term — not just the headline multiple — becomes a lever. For a practice with a VCA offer in hand, the system runs in three phases.

Phase one — diligence preparation. We pull the full financials, normalize the EBITDA against every category of owner-discretionary spend, and build the buyer-side investment memo a qualified bidder needs to underwrite the deal. For sellers facing VCA specifically, the memo also surfaces the dimensions where VCA tends to under-negotiate in direct conversations (brand preservation language, rollover liquidity mechanics, integration-roadmap commitments) so that we can make those dimensions explicit asks in the bidder packet.

Phase two — curated bidder invitation. From the 42-plus named veterinary consolidators TE actively tracks, we select only the ones whose profile fits the specific practice — geographic density, specialty mix, deal size band, integration philosophy that the seller can live with. VCA gets invited when their profile fits.

So do the brand-preservation-emphasis buyers (NVA, AmeriVet, VetCor, others) who can directly compete with VCA on the dimension that most concerns sellers protective of their practice identity.

Phase three — bidding window. Qualified bidders get a defined timeline, defined diligence access, and a final-bid deadline. The terms come back in a structured side-by-side comparison: cash at close, earnout, rollover or partnership equity, non-compete, post-sale role, brand-handling commitments, integration roadmap.

The seller chooses on the dimensions that matter to her — not always the highest headline multiple, sometimes the offer with the strongest brand-preservation language at a slightly lower headline.

The economic result holds across deal types and buyer mixes: practices in the qualifying revenue band that run our process consistently clear materially higher total economic value — typically multiple seven figures, sometimes more — than the same practice would have cleared in a direct single-bidder conversation with VCA or any other major buyer.

Closing thought

The honest read on VCA: it remains the most institutionally established veterinary buyer in the United States, with operational depth — the Antech reference lab, the continuing-education programming, the regional clinical networks — that most PE-backed competitors cannot match on day one. The Mars family ownership behind VCA is a genuinely different long-term posture than a fund-cycle buyer, and for sellers comfortable with brand transition the platform offers a stable post-sale home.

The dimension that determines whether a specific VCA transaction lands well for a specific seller, though, is not the headline multiple. It is the brand-handling and integration-timeline language in the definitive purchase agreement.

That dimension is where VCA differs most from the rest of the major buyer pool, and it is where the negotiation deserves at least as much attention as the price.

If a VCA offer is in your hand right now — or if a VCA representative has reached out and you are weighing whether to engage — the next move is to know what the rest of the market would pay for the same practice on different brand-handling terms, before you commit to anything. Get a Free Practice Value Estimate and we’ll lay out the comparison the way we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

VCA Animal Hospitals and parent company materials

6. VCA Animal Hospitals. About VCA, US hospital network, and integration platform. VCA company materials, 2024-2026.
7. Mars, Incorporated. Mars Veterinary Health overview and US division structure. Mars company materials, 2024-2026.
8. Antech Diagnostics. About Antech reference laboratory network. Antech company materials, 2024-2026.

Historical transaction references

9. SEC filings. Mars Inc. acquisition of VCA Inc., 2017. US Securities and Exchange Commission EDGAR archive.

Veterinary practice operations, benchmarks, and profession data

10. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
11. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.